Consortium Member(s) of the Month
Our FIRST EVER consortium members of the month for the month of April goes to Blake Langlais and Duke Butterfield from our REDCap team over at Mayo Clinic, Arizona!
Blake Langlais, MS
Blake received his MS degree in Statistics at UC Davis. He joined Mayo Clinic in 2016 and previously served as a quality improvement analyst at the Arizona Department of Health Services, and as an informatics analyst at Mercer. Blake is a Principal Biostatistician at Mayo Clinic with expertise in both SAS and R programming, data modeling, and patient-reported outcomes. He has provided biostatistical support for MPN-RC Projects since joining Mayo Clinic, including managing the tissue bank database and data queries. He has been instrumental in creating and managing data pipelines for the multiple sources of tissue bank data during and after the move of the physical tissue bank to Mt. Sinai. Blake has led multiple papers including exploration of the impact of gender representativeness in online symptom surveys and clinical trials (Langlais B, et al. Leuk Lymphoma. 2024; 65[10]:1465-1473) and validation of a modified version of the Myeloproliferative Neoplasm Symptom Assessment Form Total Symptom Score (Langlais BT, et al. J Hematol. 2021; 10[5]:207-211), which were directly informed by work of the MPN-RC. Outside of the MPN-RC, Blake collaborates with investigators on Neurology and Transplant projects, including a large observational cohort of individuals at high risk for Alzheimer’s disease and a study assessing lung transplantation outcomes. In his free time, Blake is an avid hiker, handyman, and dog dad.
Written by: Amylou Dueck, PhD (Core C Project Leader)
Duke Butterfield, MA
Duke received his MA degree in Policy Economics from Tulane in 2017 and joined Dr. Dueck’s team at Mayo Clinic shortly thereafter. Duke is a Principal Statistical Programmer at Mayo Clinic with expertise in SAS programming, building complex databases in RedCap, data report creation, and team communication. He has provided statistical programming support for MPN-RC Projects since joining Mayo Clinic, including developing electronic case report forms and activating all our clinical trials in RedCap. Outside of the MPN-RC, Duke collaborates with investigators on Dermatology, Transplant, and Neurology projects including headache trials. Duke has also supported and mentored numerous Medical Students in early research endeavors. Duke serves as the Chair of the Quantitative Health Sciences Department Communications Committee. He also takes the initiative to organize our annual Fantasy Football league and March Madness brackets. Duke is a recent new father, so the new addition to his life is keeping him happy and busy.
Written by: Amylou Dueck, PhD (Core C Project Leader)
Blake and Duke, thank you so much for the continuous, phenomenal work you have both done for the consortium.
Keep up the great work!
Title: Pelabresib plus ruxolitinib for JAK inhibitor-naive myelofibrosis: a randomized phase 3 trial
Author(s): Raajit K. Rampal, Sebastian Grosicki, Dominik Chraniuk, Elisabetta Abruzzese, Prithviraj Bose, Aaron T. Gerds, Alessandro M. Vannucchi, Francesca Palandri, Sung-Eun Lee, Vikas Gupta, Alessandro Lucchesi, Stephen T. Oh, Andrew T. Kuykendall, Andrea Patriarca, Alberto Álvarez-Larrán, Ruben Mesa, Jean-Jacques Kiladijan, Moshe Talpaz, Joseph M. Scandura, David Lavie, Morgan Harris, Sarah-Katharina Kays, Qing Li, Rainer Boxhammer, Barbara Brown, Anna-Maria Jegg, Claire N. Harrison & John Mascarenhas
MPN-RC Monthly Publication
We are HIRING!
Job Title: Clinical Research Coordinator I
Institution: Mount Sinai Health System
APPLY HERE!
*After applying for the position, please email your resume to Research Program Director Claire Borron at claire.borron@mssm.edu*
MPN-RC Updates: ASH Conference 2024
-
Bridget Kelly Marcellino, MD,PhD
873 Molecular Consequences and Targeting of PPM1D Mutations and Overexpression in Myeloproliferative Neoplasm Stem Cells
-
Shivani Handa, MD
243 TP53 Alterations Confer Increased Risk of Leukemic Transformation and Worse Survival As Compared to High Molecular Risk Mutations in Patients with Myeloproliferative Neoplasms